Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | KMO | O15229 | 5/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8650544 | 0.79 | VCP (0.58) | TSHRSRD5A2KMOHSD11B1MEN1 | |
| SCHEMBL8625862 | 0.79 | HPGD (0.49) | TSHRSRD5A2KMOKDM4EMEN1 | |
| SCHEMBL23522691 | 0.76 | TSHR (0.57) | TSHRSRD5A2KMOHSD11B1KDM4E | |
| SCHEMBL5667979 | 0.76 | TSHR (0.57) | TSHRSRD5A2KMOKDM4EMEN1 | |
| SCHEMBL23484631 | 0.75 | TSHR (0.46) | TSHRKMOKDM4EMAPT | |
| SCHEMBL371998 | 0.74 | TSHR (1.00) | TSHRSRD5A2KMOKDM4EMEN1 | |
| SCHEMBL29353637 | 0.74 | TSHR (1.00) | TSHRSRD5A2KMOKDM4EMEN1 | |
| SCHEMBL8352471 | 0.74 | TSHR (1.00) | TSHRSRD5A2KMOKDM4EMEN1 | |
| SCHEMBL28142605 | 0.73 | CES2 (0.55) | KDM4EMEN1NPC1RAB9AKMT2A | |
| Hydrochloric Acid SCHEMBL11133785 | 0.73 | TSHR (0.95) | TSHRSRD5A2KMOKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573898-B | Treat and prevent hepatitis b virus infected new pyridazinone and triazinone | 豪夫迈·罗氏有限公司 | 2018-11-09 | — | — | CN | disclosed |
| CN-106573898-A | Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2017-04-19 | — | — | CN | disclosed |
| US-7649009-B2 | N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis | MERCK & CO., INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-1765335-B1 | PYRAZOLE AMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | MERCK & CO., INC. (US) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203186-A1 | Pyrazole Amide Derivatives, Compositions Containing Such Compounds And Methods Of Use | AADAC, GOT2, GLS2 | TSHR 2190/4885SRD5A2 781/4885KMO 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.